Esperion Therapeutics, Inc. (ESPR) on Tuesday said HLS Therapeutics Inc. (HLS), its partner in Canada for NILEMDO, has received Health Canada approval to market NILEMDO for reducing LDL-cholesterol in people who are at risk of cardiovascular disease.
The commercial launch is expected in the second quarter of 2026.
About one in 12 Canadian adults aged 20 and over, roughly 2.6 million people, live with diagnosed heart disease, according to the Government of Canada.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.